Independent report · Venture Debt / Structured Credit

India Venture Debt Funds: Trifecta vs Alteria vs Stride

May 30, 2026 · By Anurag

Rahul Khanna, Trifecta Capital managing partner

Independent report content

RUPEIA · PRIVATECREDITNOTE · VENTUREDEBTREPORT # 0 0 1

INDIAVENTUREDEBT · HEAD - T O - HEAD

VC-Ecosystem Risk In Debt Clothing Trifecta Capital · Stride Ventures · Alteria Capital · InnoVen Capital India venture debt: $1.3B deployed, 187 deals in 2025 June 2026

DEEPEST TRACK

₹2,000Cr IV Trifecta Capital

ANCHOR · IFC-VALIDATED

₹8,350 Cr+ across 4 funds; 18 unicorns, 8 IPOs. IFC committed $25M to Fund

IV. The deepest, most

accessible track.

YIELD 16, 17% IRR;

20%+ on good

deals

TEAM Rahul Khanna + Nilesh Kothari FLAG BluSmart sector stress

MOST ACTIVE

$300MIV Stride Ventures

BREADTH · CROSS-BORDER

121 deals in 2025, the most active. Fund I fully

returned. GCC + UK

funds add cross-border

exposure. YIELD 13, 16% gross + warrants TEAM Gandhi + Apoorva Sharma TRACK $1B+ deployed, 12 unicorns

SHORTER DURATION

$540MAUM Alteria Capital

CONSERVATIVE · IFC SDS

Ex-SVB/InnoVen founders. Standard 18, 36mo + a Shorter Duration Scheme (9, 18mo) with an IFC anchor.

YIELD 13, 15%; SDS 14,

16% TEAM Vinod Murali (ex- SVB India) TRACK Fund III ₹1,550 Cr, 12 exits

PIONEER · NBFC

<1%loss InnoVen Capital

17-YEAR TRACK ·

TEMASEK/UOB

India's first venture lender (2008). $850M+ deployed, 35+ unicorns, <1% loss rate. NBFC, not AIF.

YIELD 13, 17% (NBFC

margin) LEAD Ashish Sharma (MD India) RATING IND AA- term debt

RUPEIAC AT EGORYVERDICT

Venture debt is categorically different from performing credit. The primary repayment source is the startup's next equity round, not operating cash flow, and there is no hard asset collateral that independently secures repayment. The VC backing is the real guarantee, so the investor's risk is

fundamentally VC-ecosystem risk, not credit risk. An LP is implicitly betting that (1) the Indian VC

market keeps funding the portfolio and (2) the fund's selection beats the ecosystem average. Among the

four, InnoVen's <1% loss rate across 17 years is the most credible proof this bet can be won consistently.

RUPEIA INVESTMENT INTELLIGENCE | JUNE 25, 2026 | VENTURE DEBT REPORT #001 | PREPARED INDEPENDENTLY

RUPEIA INDIA VENTURE DEBT COMPARISON INDEPENDENT FUND COMPARISON

1 EXECUTIVE FIT SUMMARY

ITEM TRIFECTA STRIDE ALTERIA INNOVEN

Structure AIF + NBFC. Senior secured

NCDs to VC-backed growth startups (also Leaders equity

fund).

AIF. Senior secured term loans. India + GCC + UK + SEA. AIF. Senior secured NCDs, Series A, D. Dual scheme: standard + SDS.

NBFC (not AIF). Seed to pre-IPO. India's first venture lender (2008). Temasek + UOB JV.

Fund / AUM Fund IV ₹2,000 Cr (first close Jan

2025). ₹8,350 Cr+ cumulative. IFC $25M.

Fund IV $300M (Dec

2024). $715M+ raised; $1B+ deployed.

Fund III ₹1,550 Cr (Mar 2024)

+ SDS $100M (IFC anchor). ~$540M AUM. $850M+ deployed; 200+ companies; 35+ unicorns. IND AA- rated.

Gross return 16, 17% IRR; 20%+ on good deals (14, 15% coupon + ~5% warrant IRR). 13, 16% gross. Cash 13, 15% + warrants.

13, 15% (standard); SDS ~14, 16%. Coupon-heavy. ~15, 17% implied; <1% loss = net closely tracks gross.

Repayment

source

Next VC round (early) / operating CF (later). VC backing the real guarantee. Same, next round; VC relationships the key parameter.

Same. SDS targets shorter runway to next raise/revenue event. Same. Seed→pre-IPO; equity raise or IPO proceeds. <1% loss over 17yr.

Main risk Startup fails between rounds; BluSmart = sector-stress signal.

Funding winter; 121

deals = high-volume

credit risk. SDS higher churn; standard = same next-round risk. Same, but the most battle-tested across every India downturn since 2008.

Best for HNI/FO wanting large, diversified, high-IRR VD with IFC co-validation. LP wanting highest breadth + cross-border

(GCC/UK).

FO/institution wanting IFC- validated shorter-duration or standard VD. Institution/FO wanting oldest track, NBFC oversight, Temasek/UOB, <1% loss.

2 VENTURE DEBT: WHAT IT IS AND IS NOT

CRITICALFRAMINGFORINVESTORS

Venture debt is NOT performing credit. The central risk is not whether a manufacturer has enough EBITDA, it is whether a startup's VC backers will fund the next equity round before the debt matures. The collateral (IP, brand, receivables, personal guarantees) is a legal formality giving recovery leverage in a negotiation, not a liquidation plan, shutting a startup and selling assets recovers 10, 30 paise per rupee at best. The real protection is choosing borrowers whose VCs will not let them fail and sizing the loan small enough that repayment from next-round proceeds is certain. VC-relationship quality is the most important diligence parameter, not the security package.

DIMENSION TRIFECTA STRIDE ALTERIA INNOVEN

Stage focus Series A, D; later-stage names (Physics Wallah, Cars24). ₹10, 100 Cr. Series A, D. ₹5, 50 Cr. Largest

deal volume in market.

Series A, D; SDS earlier- stage, smaller (₹5, 30 Cr). Seed to pre-IPO, only fund doing seed-stage VD. ₹2, 200 Cr.

VC relationship quality Deepest network, co-invests with India's top 20 VCs (Peak XV, Accel, Elevation, Matrix).

121 deals/2025 = most active; broad fintech/consumer relationships + intl VCs. Ex-SVB/InnoVen network pre-dating the AIF era; deep Series A, C co-lending.

17 years, every major India VC has co-invested. Temasek = LP in many of those VCs. Borrower- quality signal 18 unicorns, 8 IPOs = proxy for selection quality.

12 unicorns; Fund I fully

returned = all borrowers repaid.

12 exits; axio (Dec 2024) clean; IFC diligence validates. 35+ unicorns; <1% loss = the most granular quality signal available.

Sector-stress

test BluSmart (EV fleet) acute distress 2025 → partial recovery + renegotiation.

Ather (EV) IPO 2025 = positive; cautious EV-fleet exposure. No major public NPA; conservative sector mix, no pure-EV fleet.

Navigated Dunzo, OYO restructuring without public NPA; <1% loss includes these.

RUPEIA INDIA VENTURE DEBT COMPARISON INDEPENDENT FUND COMPARISON

3 YIELD QUALITY TEST, RETURN COMPONENTS

COMPONENT TRIFECTA STRIDE ALTERIA INNOVEN

Cash coupon 14, 15% NCD. Strong. 13, 15% term loan. Strong. 13, 15%; SDS 14, 16%. Strong. 13, 15%; IND AA- = low funding cost preserves margin. Strong.

Equity warrants 0.1, 2%; ~5% extra IRR on exits; 18 unicorns realised. Strong. 0.1, 2%; 12 unicorns realised. Strong.

Conservative warrant sizing, coupon over warrant. Amber. 35+ unicorns = highest absolute realised warrant value (over 17yr). Strong.

PIK interest None, non-payment = default, not PIK. Strong. None. Strong. None; SDS shorter tenor removes the PIK window.

Strong. None, clean cash-pay. Strong. Recovery from default Collateral liquidation or settlement; BluSmart = partial settlement. Event-linked.

Fund I fully returned

= no default exits needed. Conservative portfolio = fewer stressed exits; IFC raises the floor.

<1% loss = best recovery track in group.

THE WA RRANTQUALITYC AV E AT

Warrants are equity options on startups that already took venture debt, their value depends on the startup achieving a liquidity event above the exercise price, the fund holding long enough, and having the conversion mechanism. Trifecta's 18 unicorns + 8 IPOs = the highest verified warrant-monetisation opportunity in the group; InnoVen's 35+ unicorns over 17yr = highest absolute realised value but spread over a much longer timeline. For an LP in Fund IV today, warrant value is a future event, not current income.

4 VC BACKING AS GUARANTEE, HOW REPAYMENT ACTUALLY

WORKS

THEINCENTIVESTRUCTURE

VD funds select borrowers whose VCs have incentive to protect them. When a startup raises Series B, the Series A VCs already have equity at risk; if it defaults on its venture debt, those VCs lose their entire stake, worth far more than the debt. The VCs therefore have strong incentive to bridge-finance a struggling company to ensure it repays and completes its next raise. The VD fund profits from this. The critical LP question: how strong are the VCs behind the portfolio, and how likely are they to bridge before a default?

DIMENSION TRIFECTA STRIDE ALTERIA INNOVEN

Top VC co- investors Peak XV, Accel, Elevation, Lightspeed, Matrix, Kalaari.

Peak XV, Accel, Blume, Lightspeed, Nexus, Ribbit. Peak XV, Accel, Lightspeed, Matrix, General Catalyst.

Every major India VC over 17yr; Temasek also LP in many of them. VC support probability in distress HIGH, 18 unicorns imply heavy follow-on; VCs don't abandon at VD-default level.

HIGH, Fund I fully

returned; VCs funded

runway extensions. HIGH, conservative + SVB-era trust; IFC validation.

HIGHEST, 17yr relationship capital; Temasek alignment with the VC ecosystem.

RUPEIA INDIA VENTURE DEBT COMPARISON INDEPENDENT FUND COMPARISON

DIMENSION TRIFECTA STRIDE ALTERIA INNOVEN

Sector

concentration Consumer 28%, fintech 24%, SaaS 20%, healthtech 12%. Broad.

Consumer 30%, fintech 25%, agritech 10%, SaaS 15%, cleantech 10%. Fintech 30%, consumer 25%, B2B 20%, climate 10%.

Fintech 30, 35%, consumer 25%, enterprise 20%, logistics 10%. Stage repayment quality Series A, D: 18, 36mo runway, clear next-round plan = HIGH.

Same; some seed = slightly lower. HIGH; SDS earlier-stage = MEDIUM, offset by shorter duration.

VARIABLE, seed lower, Series C/D higher; <1% loss validates the range.

5 COLLATERAL REALITY & CONCENTRATION STRESS TEST

THECOLL AT ERALREALITY

In venture debt, "senior secured" has limited practical protection. A startup's assets are IP (sells for 5, 20% of book), brand (zero if failed), customer relationships (transfer to competitors) and human capital (leaves). Personal guarantees from founders with ₹5 Cr net worth are irrelevant against ₹50 Cr loans. The real security is VC backing + the next equity round. The collateral framework exists to create restructuring leverage, ensure first claim on any asset sale, and deter voluntary default, none of these four funds are exceptions.

DIMENSION TRIFECTA STRIDE ALTERIA INNOVEN

Enforcement

structure

AIF, NCLT/IBC, slower, requires consortium vote. AIF, same. AIF, same. NBFC, SARFAESI applies, faster recovery. Material structural advantage.

Practical recovery (est.) 10, 25 paise/rupee from assets; warrant value zero in distress.

Fund I fully returned =

collateral never tested in extremis. No major default = collateral untested.

<1% loss = near-zero realised liquidation losses.

Portfolio

companies 210 total (10yr); Fund IV 50, 75 targeted. 209 total (7yr); ~60, 80 targeted. Highest volume.

135 total; Fund III 40, 60; SDS smaller. 200+ over 17yr; continuous NBFC lending.

Per-company concentration ~1.35, 2.0% per company. Well diversified.

~1.25, 1.7%. Excellent diversification. ~1.7, 2.5%; SDS even smaller.

Continuous churn of 18, 36mo loans auto-reduces concentration.

Funding-winter

stress test

Funds I, III navigated 2022,

23; Fund III closed at the peak of the winter.

Fund III closed May 2024;

Fund I returned despite the

winter.

Fund III Mar 2024; IFC

anchored the SDS during a cautious market. 17yr, zero fund wind-ups through 2011, 2016, COVID, 2022, 23. The definitive test.

6 MANAGER QUALITY, TEAM & MONITORING

DIMENSION TRIFECTA STRIDE ALTERIA INNOVEN

Founding team Rahul Khanna + Nilesh Kothari (2015). 73 people. Ishpreet Singh Gandhi + Apoorva Sharma (2019).

Fastest-growing. Vinod Murali + Punit Shah + Ankit Agarwal; Ajay Hattangdi (founding, retired).

Ashish Sharma (CEO India) + SVB/InnoVen heritage; Temasek + UOB governance. SVB India lineage Adjacent-era roles, not direct staff.

None, second-generation VD team. DIRECT, Murali + Hattangdi built SVB India / InnoVen.

Deepest expertise. IS the lineage, InnoVen WAS SVB India Finance. Monitoring Monthly MIS, credit committee, runway early- warning.

Same; 209 active companies = heavy monitoring load. Standard; SDS shorter = faster feedback loops.

RBI-mandated NBFC monitoring + IND AA- maintenance = most rigorous external requirement.

RUPEIA INDIA VENTURE DEBT COMPARISON INDEPENDENT FUND COMPARISON

DIMENSION TRIFECTA STRIDE ALTERIA INNOVEN

Post-investment value-add Trifecta Treasury, CFO treasury platform for

portfolio startups.

GCC + UK relationships for international expansion. Deep fintech sector relationships; fundraising advisory.

Temasek global network access for

portfolio companies.

7 FEES, NET YIELD & DISTRIBUTION RELIABILITY

METRIC TRIFECTA STRIDE ALTERIA INNOVEN

Gross yield target 16, 17% IRR; 20%+ good deals; 15% coupon floor.

13, 16% gross. 13, 15%; SDS 14, 16%. Coupon-first. 13, 17% (NBFC margin); <1% loss = net tracks gross.

Net pre-tax (est.) 12, 15% coupon + 3, 5% warrant (event- linked) = 14, 17% for good outcomes.

11, 14% net coupon + warrant upside. 11, 13% standard; SDS 13, 15% (less fee drag).

Institutional spread; strong net preservation. Distribution Quarterly coupon; principal amortised; warrant events add non- coupon distributions.

Monthly/quarterly; 121 deals/yr = continuous reinvestment. Quarterly; SDS shorter = faster return of capital.

Regular from Year 2; NBFC = cleaner timing. Distribution reliability HIGH, 18 unicorns + 8 IPOs + live coupon book.

HIGH, Fund I fully returned; stable income book. HIGH, conservative + SDS faster + IFC floor.

HIGHEST, <1% loss / 17yr /

IND AA-.

8 INVESTOR FIT MATRIX

LP TYPE TRIFECTA STRIDE ALTERIA INNOVEN

First-time VD HNI

BEST START, IFC, 18

unicorns, ₹1 Cr min, 50, 75 cos. 2nd option, broadest diversification; 121 deals = monitoring strain.

SDS IDEAL, 9, 18mo, faster

return, IFC anchor.

NOT ACCESSIBLE, NBFC, no AIF route. Family office (full sleeve)

ANCHOR, 40, 50% of VD sleeve.

COMPLEMENT, 30, 40%;

GCC/UK cross-border.

CONSERVATIVE ADD, 15,

20%; SDS shortens duration. IF ACCESSIBLE, 15, 20% via institutional relationship. Institution

(IRDAI / NPS /

CVC) SUITABLE, Cat II AIF, IFC co-validated. SUITABLE, Cat II AIF, GCC exposure.

SDS BEST FIT, IFC + short duration + AIF.

MOST SUITABLE, IND AA-,

NBFC, Temasek; rated-debt eligibility. Corporate treasury (12, 24mo)

Too long (18, 36mo). Too long. ONLY OPTION, SDS 9, 18mo + IFC ESMS governance. N/A, NBFC, not a treasury instrument.

9 WHAT MUST BE TRUE, FINAL VIEW

For all four funds to deliver, four things must hold: (1) the India VC ecosystem keeps funding Series A, D, a sustained >40% contraction over 24+ months breaks the next-round repayment mechanism industry-wide; (2) the VC backing behind each portfolio company stays active (a VC in its final deployment year is weaker backing than one that just closed a fresh corpus); (3) startup failure rates don't spike beyond the ~6, 8 defaults a fund can absorb at 2% concentration before missing net targets; and (4) warrant value remains realisable, in a depressed IPO market the 15, 17% gross without warrant contribution must itself be acceptable.

RUPEIA INDIA VENTURE DEBT COMPARISON INDEPENDENT FUND COMPARISON

1 Trifecta Capital Fund IV, Best starting point AIF Cat II. IFC co-invested. 18 unicorns, 8 IPOs. ₹1 Cr minimum.

RUPEIA CALL: ANCHOR THE VD SLEEVE. DEEPEST TRACK + MOST ACCESSIBLE. 16, 17% IRR FOR SENIOR-SECURED

VC-BACKED LENDING IS APPROPRIATELY PRICED.

2 InnoVen Capital, Highest-quality credit, if accessible NBFC, not AIF. <1% loss across 17 years. Temasek + UOB. IND AA-.

RUPEIA CALL: MOST SUITABLE FOR INSTITUTIONS REQUIRING NBFC-GRADE QUALITY AND RATED-DEBT

ELIGIBILITY. ACCESS REQUIRES AN INSTITUTIONAL RELATIONSHIP.

3 Alteria Capital SDS, Shorter duration, conservative 9, 18mo Shorter Duration Scheme with an IFC anchor.

RUPEIA CALL: BEST FOR CORPORATE TREASURY AND CONSERVATIVE LPS. THE ONLY VD PRODUCT FITTING A 12,

24MO MANDATE; IFC ESMS GOVERNANCE.

4 Stride Ventures Fund IV, Most active, cross-border 121 deals in 2025; Fund I fully returned; GCC + UK.

RUPEIA CALL: COMPLEMENT FOR BREADTH AND INTERNATIONAL EXPOSURE. RESOLVE THE HIGH-VOLUME

MONITORING QUESTION BEFORE SIZING UP.

THERUPEIACENTRALQUESTION , ANSWERED

Is the investor paid enough yield for the actual repayment, collateral, recovery and

liquidity risk? Trifecta: yes for an HNI/FO with VC-ecosystem conviction, 16, 17%

IRR with IFC validation and 18 unicorns is appropriately priced. Stride: yes for maximum breadth. Alteria SDS: yes for shorter duration and conservative risk. InnoVen: yes for institutions requiring NBFC-grade quality, its <1% loss rate across 17 years is the most credible venture-debt track record in India, but it is not accessible via the AIF route.

RUPEIAVERDICT

Venture debt is VC-ecosystem risk in debt clothing, price it as such. Trifecta anchors the sleeve; InnoVen is the highest-quality credit for institutions; Alteria SDS suits shorter-duration and treasury mandates; Stride adds breadth and cross-border exposure. The systemic risk, a sustained VC

funding contraction, is one no single fund selection can avoid, so size the sleeve accordingly.

RUPEIA INDIA VENTURE DEBT COMPARISON INDEPENDENT FUND COMPARISON

10 SOURCE LOG

REF SOURCE DATE KEY DATA CONFIDENCE

[1] Equitylist.co (Venture Debt Guide) Mar 2026 Alteria AUM $540M; Fund III ₹1,550 Cr; IFC SDS anchor; Stride $1B;

market ₹10,300 Cr 2024

HIGH [2] Stride / Inc42 / YourStory Dec 2024 Fund IV $300M; Fund I fully returned; $1B+ deployed HIGH [3] Inc42, Trifecta Fund III / IV deck 2021 / 2024 Khanna "20% good deals, 15% bad"; 14, 15% coupon + ~5% kicker; Fund IV ₹2,000 Cr, 16, 17% IRR HIGH [4] IFC disclosure portal (Alteria SDS)

Mar 2025 IFC $12M in Alteria SDS; $100M target; short-duration VD HIGH, primary [5] InnoVen website + LinkedIn 2024, 26 $850M+ deployed; 200+ cos; 35+ unicorns; <1% loss; Temasek + UOB;

IND AA-

HIGH, primary [6] Tracxn (Trifecta + Stride) Oct 2025 / Jun Trifecta 210 cos, 18 unicorns, 8 IPOs; Stride 209 cos, 12 unicorns, 121

deals 2025

HIGH [7] Angelone.in, VD 2025 report Apr 2026 India VD 2025: $1.3B, 187 deals; fintech 46%; Stride 121 deals top; Alteria HIGH The Standard Venture debt is not performing credit, the repayment source is the next equity round, and the collateral is a negotiating tool, not a liquidation plan. The real protection is VC backing. Trifecta anchors, InnoVen is the institutional-quality benchmark (<1% loss over 17 years), Alteria SDS fits shorter duration, and Stride adds breadth. Size the sleeve for the systemic risk no single fund can avoid: a sustained contraction in India VC funding.

DISCLAIMER

This document is published strictly for informational, educational, and academic record-keeping purposes only. The publisher of this document is not a SEBI Registered Investment Adviser (RIA), nor a SEBI Registered Research Analyst (RA). This report does not constitute personal investment advice, an independent research report, a financial recommendation, or an offer or solicitation to buy, sell, or subscribe to any securities. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

RUPEIA | VENTUREDEBTREPORT # 0 0 1 | TRIFEC TA · STRIDE · A LT ERIA · INNOVEN | JUNE 2 5 , 2 0 2 6

RUPEIA INDIA VENTURE DEBT COMPARISON INDEPENDENT FUND COMPARISON